Pembrolizumab

About

Therapy type: Immunotherapy

Therapy strategy: PD-1/PD-L1 inhibition

Mappings

NCI Thesaurus: Pembrolizumab (ncit:C106432)

RxNorm: pembrolizumab (rxcui:1547545, omop:45775965)

SNOMED: Pembrolizumab (sctid:716125002, omop:37396350)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
EMA (1) FDA (1) HSE (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Pembrolizumab, Pemetrexed
EMA (1) FDA (1) HSE (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Pembrolizumab, Pemetrexed
FDA (1) PD-L1 >= 1%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Pembrolizumab
EMA (1) FDA (1) PD-L1 >= 1% Non-Small Cell Lung Cancer Pembrolizumab
EMA (1) FDA (2) HSE (2) PD-L1 (CPS) >= 1 Head and Neck Squamous Cell Carcinoma Pembrolizumab
FDA (1) dMMR Any solid tumor Pembrolizumab
FDA (1) MSI-H Any solid tumor Pembrolizumab
EMA (1) FDA (1) HSE (1) dMMR Colorectal Adenocarcinoma Pembrolizumab
EMA (1) FDA (1) HSE (2) MSI-H Colorectal Adenocarcinoma Pembrolizumab
EMA (1) FDA (1) HER2-positive, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Pembrolizumab, Trastuzumab
FDA (1) HER2-positive, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Pembrolizumab, Trastuzumab
FDA (1) HER2-negative Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Pembrolizumab
FDA (1) HER2-negative Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Pembrolizumab
FDA (1) PD-L1 (CPS) >= 10 Adenocarcinoma of the Gastroesophageal Junction Pembrolizumab
FDA (1) PD-L1 (CPS) >= 10 Esophageal Adenocarcinoma Pembrolizumab
FDA (1) PD-L1 (CPS) >= 1 Cervical Adenocarcinoma Cisplatin, Paclitaxel, Pembrolizumab
FDA (1) PD-L1 (CPS) >= 1 Cervical Squamous Cell Carcinoma Cisplatin, Paclitaxel, Pembrolizumab
FDA (1) PD-L1 (CPS) >= 1 Cervical Adenocarcinoma Bevacizumab, Cisplatin, Paclitaxel, Pembrolizumab
FDA (1) PD-L1 (CPS) >= 1 Cervical Squamous Cell Carcinoma Bevacizumab, Cisplatin, Paclitaxel, Pembrolizumab
EMA (1) FDA (1) HSE (1) PD-L1 (CPS) >= 1 Cervical Adenocarcinoma Carboplatin, Paclitaxel, Pembrolizumab
FDA (1) PD-L1 (CPS) >= 1 Cervical Squamous Cell Carcinoma Carboplatin, Paclitaxel, Pembrolizumab
EMA (1) FDA (1) HSE (1) PD-L1 (CPS) >= 1 Cervical Adenocarcinoma Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab
FDA (1) PD-L1 (CPS) >= 1 Cervical Squamous Cell Carcinoma Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab
FDA (1) HSE (2) PD-L1 (CPS) >= 1 Cervical Adenocarcinoma Pembrolizumab
FDA (1) PD-L1 (CPS) >= 1 Cervical Squamous Cell Carcinoma Pembrolizumab
FDA (1) MSI-L Endometrial Carcinoma Lenvatinib, Pembrolizumab
FDA (1) pMMR Endometrial Carcinoma Pembrolizumab
EMA (1) FDA (1) MSI-H Endometrial Carcinoma Pembrolizumab
FDA (1) TMB-H (>= 10 mutations / Mb) Any solid tumor Pembrolizumab
FDA (1) HSE (4) ER negative, HER2-negative, PR negative Invasive Breast Carcinoma Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel, Pembrolizumab
EMA (1) FDA (1) ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative Invasive Breast Carcinoma Paclitaxel, Pembrolizumab
EMA (1) FDA (1) ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative Invasive Breast Carcinoma Carboplatin, Gemcitabine, Pembrolizumab
EMA (1) HSE (2) PD-L1 >= 50%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Pembrolizumab
EMA (1) HSE (1) CD274 amplification, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Pembrolizumab
EMA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Gemcitabine, Pembrolizumab
EMA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Gemcitabine, Pembrolizumab
EMA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Paclitaxel, Pembrolizumab
EMA (1) HSE (2) PD-L1 (CPS) >= 10 Bladder Urothelial Carcinoma Pembrolizumab
EMA (1) HSE (1) PD-L1 (CPS) >= 1 Head and Neck Squamous Cell Carcinoma Carboplatin, Fluorouracil, Pembrolizumab
EMA (1) HSE (1) PD-L1 (CPS) >= 1 Head and Neck Squamous Cell Carcinoma Cisplatin, Fluorouracil, Pembrolizumab
EMA (1) PD-L1 >= 50% Head and Neck Squamous Cell Carcinoma Pembrolizumab
EMA (1) dMMR Endometrial Carcinoma Pembrolizumab
EMA (1) MSI-H Esophagogastric Adenocarcinoma Pembrolizumab
EMA (1) dMMR Esophagogastric Adenocarcinoma Pembrolizumab
EMA (1) MSI-H Gastrointestinal Stromal Tumor Pembrolizumab
EMA (1) dMMR Gastrointestinal Stromal Tumor Pembrolizumab
EMA (1) MSI-H Cholangiocarcinoma Pembrolizumab
EMA (1) dMMR Cholangiocarcinoma Pembrolizumab
EMA (1) HSE (1) PD-L1 (CPS) >= 10 Esophageal Adenocarcinoma Cisplatin, Fluorouracil, Pembrolizumab
EMA (1) PD-L1 (CPS) >= 10 Esophageal Adenocarcinoma Carboplatin, Fluorouracil, Pembrolizumab
EMA (1) ER negative, HER2-negative, PR negative Invasive Breast Carcinoma Pembrolizumab
EMA (1) ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative Invasive Breast Carcinoma Nab-paclitaxel, Pembrolizumab
EMA (1) HER2-positive, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Carboplatin, Fluorouracil, Pembrolizumab, Trastuzumab
EMA (1) HER2-negative, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Pembrolizumab
EMA (1) HER2-negative, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Carboplatin, Fluorouracil, Pembrolizumab
HSE (1) HER2-negative, PD-L1 (CPS) >= 10 Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Pembrolizumab
HSE (1) HER2-negative, PD-L1 (CPS) >= 10 Adenocarcinoma of the Gastroesophageal Junction Fluorouracil, Oxaliplatin, Pembrolizumab
FDA (1) PD-L1 (CPS) >= 1 Ovarian Epithelial Tumor Paclitaxel, Pembrolizumab
FDA (1) PD-L1 (CPS) >= 1 Ovarian Epithelial Tumor Bevacizumab, Paclitaxel, Pembrolizumab
FDA (1) PD-L1 (CPS) >= 1 High-Grade Serous Fallopian Tube Cancer Paclitaxel, Pembrolizumab
FDA (1) PD-L1 (CPS) >= 1 High-Grade Serous Fallopian Tube Cancer Bevacizumab, Paclitaxel, Pembrolizumab
FDA (1) PD-L1 (CPS) >= 1 Peritoneal Serous Carcinoma Paclitaxel, Pembrolizumab
FDA (1) PD-L1 (CPS) >= 1 Peritoneal Serous Carcinoma Bevacizumab, Paclitaxel, Pembrolizumab